Individualization of antithrombotic therapy

Coronary heart disease (CHD) is one of the most common heart diseases worldwide and is currently grouped into two syndromes: acute coronary syndrome (ACS) and chronic coronary syndrome (CCS). Following revascularization, patients with ACS and CCS are usually treated in the medium and long term by both general practitioners and cardiologists. The current guidelines of the European Society of Cardiology (ESC) emphasize that the assessment of the individual ischemia and bleeding risk is an important basis for the choice of an adequate antithrombotic strategy.